

# Liliane Massade

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7006496/publications.pdf>

Version: 2024-02-01

42  
papers

1,103  
citations

331670

21  
h-index

414414

32  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1573  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery. <i>Bioconjugate Chemistry</i> , 2012, 23, 1091-1104.	3.6	131
2	Synthesis, Characterization, and in Vivo Delivery of siRNA-Squalene Nanoparticles Targeting Fusion Oncogene in Papillary Thyroid Carcinoma. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4067-4076.	6.4	75
3	Pro-atherogenic effect of interleukin-4 in endothelial cells: Modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. <i>Atherosclerosis</i> , 2006, 187, 285-291.	0.8	71
4	Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. <i>Carcinogenesis</i> , 2001, 22, 1819-1824.	2.8	61
5	How can chemical compounds alter human fertility?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2002, 100, 127-137.	1.1	47
6	Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 315-326.	5.1	47
7	Small interfering RNA from the lab discovery to patients' recovery. <i>Journal of Controlled Release</i> , 2020, 321, 616-628.	9.9	42
8	Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 1993, 14, 1279-1283.	2.8	41
9	Hypoxia Down-regulates CCAAT/Enhancer Binding Protein-1 Expression in Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 2158-2165.	0.9	40
10	Title is missing!. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 339-347.	5.7	36
11	Transactivation of the Metallothionein Promoter in Cisplatin-Resistant Cancer Cells: a Specific Gene Therapy Strategy. <i>Journal of the National Cancer Institute</i> , 2000, 92, 642-647.	6.3	33
12	Wnt/ $\beta$ -Catenin Signaling Pathway Is a Direct Enhancer of Thyroid Transcription Factor-1 in Human Papillary Thyroid Carcinoma Cells. <i>PLoS ONE</i> , 2011, 6, e22280.	2.5	32
13	Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A. <i>Communications Biology</i> , 2021, 4, 317.	4.4	31
14	Treating PMP22 gene duplication-related Charcot-Marie-Tooth disease: the past, the present and the future. <i>Translational Research</i> , 2021, 227, 100-111.	5.0	30
15	Significance and applications of nanoparticles in siRNA delivery for cancer therapy. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 403-412.	3.1	26
16	Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0125277.	2.5	26
17	Discovery of New Fusion Transcripts in a Cohort of Pediatric Solid Cancers at Relapse and Relevance for Personalized Medicine. <i>Molecular Therapy</i> , 2019, 27, 200-218.	8.2	26
18	Cytogenetic studies in three xenografted nasopharyngeal carcinomas. <i>Cancer Genetics and Cytogenetics</i> , 1993, 66, 11-15.	1.0	25

#	ARTICLE	IF	CITATIONS
19	Induction of TTF-1 or PAX-8 expression on proliferation and tumorigenicity in thyroid carcinomas. International Journal of Oncology, 2016, 49, 1248-1258.	3.3	25
20	Structure and polymorphisms of human aryl hydrocarbon receptor repressor (AhRR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. Pharmacogenetics and Genomics, 2003, 13, 339-47.	5.7	25
21	Effects of Silencing the RET/PTC1 Oncogene in Papillary Thyroid Carcinoma by siRNA-Squalene Nanoparticles With and Without Fusogenic Companion GALA-Cholesterol. Thyroid, 2014, 24, 327-338.	4.5	21
22	Hypoxia and estrogen co-operate to regulate gene expression in T-47D human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2007, 104, 169-179.	2.5	20
23	New Formulation for the Delivery of Oligonucleotides Using Clickable siRNA-Polyisoprenoid-Conjugated Nanoparticles: Application to Cancers Harboring Fusion Oncogenes. Bioconjugate Chemistry, 2018, 29, 1961-1972.	3.6	17
24	Biclonal chromosome evolution of chronic myelomonocytic leukemia in a child. Cancer Genetics and Cytogenetics, 1990, 44, 131-137.	1.0	16
25	HMGA1 Enhances the Transcriptional Activity and Binding of the Estrogen Receptor to Its Responsive Element. Biochemistry, 2002, 41, 2760-2768.	2.5	15
26	Main Drug-Metabolizing Enzyme Systems in Human Non-Hodgkin's Lymphomas Sensitive or Resistant to Chemotherapy. Leukemia and Lymphoma, 1995, 18, 303-310.	1.3	14
27	Recruitment of the p160 coactivators by the glucocorticoid receptor: Dependence on the promoter context and cell type but not hypoxic conditions. Journal of Steroid Biochemistry and Molecular Biology, 2007, 104, 305-311.	2.5	14
28	ADH activity and ethanol tolerance in third chromosome substitution lines in Drosophila melanogaster. Heredity, 1989, 62, 35-44.	2.6	13
29	Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations. PLoS ONE, 2014, 9, e95964.	2.5	13
30	Effects of Silencing RET/PTC1 Junction Oncogene in Human Papillary Thyroid Carcinoma Cells. Thyroid, 2010, 20, 1053-1065.	4.5	12
31	Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues. Head and Neck, 1994, 16, 158-164.	2.0	11
32	Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide. Molecular Therapy - Nucleic Acids, 2016, 5, e301.	5.1	11
33	Unusual karyotypic evolution in subacute myelomonocytic leukemia in two monozygotic twins. Cancer Genetics and Cytogenetics, 1989, 38, 205-213.	1.0	9
34	Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leukemia Research, 1994, 18, 829-835.	0.8	8
35	Effects of natural environment on reproductive histo-morphometric dynamics of female dromedary camel. Animal Reproduction Science, 2017, 181, 30-40.	1.5	8
36	A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin. Oncotarget, 2019, 10, 1284-1305.	1.8	8

#	ARTICLE	IF	CITATIONS
37	Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression. <i>Oncogene</i> , 2019, 38, 7200-7215.	5.9	7
38	The functional interaction between HMGA1 and the estrogen receptor requires either the N- or the C-terminal domain of the receptor. <i>FEBS Letters</i> , 2004, 559, 89-95.	2.8	4
39	A single d(GpC) cisplatin adduct on the estrogen response element decreases the binding of the estrogen receptor. <i>FEBS Letters</i> , 2000, 466, 49-53.	2.8	3
40	Supramolecular organization and biological interaction of squalenoyl siRNA nanoparticles. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121117.	5.2	3
41	High catabolism of BrdU may explain unusual sister chromatid differentiation and replication banding patterns in cancer cells. <i>Cancer Genetics and Cytogenetics</i> , 1991, 53, 23-34.	1.0	2
42	Reply to Letter to the Editor from Frank Welsch. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2003, 106, 92-95.	1.1	1